DarioHealth Corp. (DRIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
DRIO POWR Grades
- Growth is the dimension where DRIO ranks best; there it ranks ahead of 76.43% of US stocks.
- DRIO's strongest trending metric is Stability; it's been moving up over the last 177 days.
- DRIO's current lowest rank is in the Momentum metric (where it is better than 1.17% of US stocks).
DRIO Stock Summary
- DRIO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 19.05% of US stocks.
- With a year-over-year growth in debt of 9,672.82%, DARIOHEALTH CORP's debt growth rate surpasses 99.58% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for DRIO comes in at -58.82% -- higher than that of only 9.66% of stocks in our set.
- Stocks that are quantitatively similar to DRIO, based on their financial statements, market capitalization, and price volatility, are IGC, RSKD, PAVM, STXS, and AFRM.
- Visit DRIO's SEC page to see the company's official filings. To visit the company's web site, go to mydario.com.
DRIO Valuation Summary
- In comparison to the median Healthcare stock, DRIO's price/sales ratio is 19.15% lower, now standing at 3.8.
- DRIO's price/sales ratio has moved NA NA over the prior 120 months.
Below are key valuation metrics over time for DRIO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DRIO | 2023-03-24 | 3.8 | 1.3 | -1.6 | -1.4 |
| DRIO | 2023-03-23 | 3.8 | 1.3 | -1.7 | -1.4 |
| DRIO | 2023-03-22 | 4.0 | 1.4 | -1.8 | -1.5 |
| DRIO | 2023-03-21 | 4.0 | 1.4 | -1.7 | -1.4 |
| DRIO | 2023-03-20 | 3.7 | 1.3 | -1.6 | -1.3 |
| DRIO | 2023-03-17 | 3.8 | 1.3 | -1.6 | -1.3 |
DRIO Growth Metrics
- Its 2 year net income to common stockholders growth rate is now at -198.41%.
- The 5 year net cashflow from operations growth rate now stands at -74.04%.
- The 5 year cash and equivalents growth rate now stands at 461.8%.
The table below shows DRIO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 26.875 | -55.04 | -73.025 |
| 2022-06-30 | 25.899 | -56.78 | -79.831 |
| 2022-03-31 | 24.977 | -57.971 | -79.623 |
| 2021-12-31 | 20.513 | -50.409 | -78.766 |
| 2021-09-30 | 16.565 | -42.033 | -66.359 |
| 2021-06-30 | 12.978 | -33.39 | -50.907 |
DRIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DRIO has a Quality Grade of F, ranking ahead of 2.68% of graded US stocks.
- DRIO's asset turnover comes in at 0.156 -- ranking 147th of 186 Medical Equipment stocks.
- SPNE, ATRI, and ICAD are the stocks whose asset turnover ratios are most correlated with DRIO.
The table below shows DRIO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.156 | 0.284 | 28.266 |
| 2021-03-31 | 0.174 | 0.296 | 38.633 |
| 2020-12-31 | 0.266 | 0.332 | 847.338 |
| 2020-09-30 | 0.283 | 0.384 | 132.027 |
| 2020-06-30 | 0.404 | 0.439 | -93.685 |
| 2020-03-31 | 0.426 | 0.403 | -274.333 |
DRIO Price Target
For more insight on analysts targets of DRIO, see our DRIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.53 | Average Broker Recommendation | 1.5 (Moderate Buy) |
DRIO Stock Price Chart Interactive Chart >
DRIO Price/Volume Stats
| Current price | $4.01 | 52-week high | $7.69 |
| Prev. close | $3.95 | 52-week low | $3.53 |
| Day low | $3.96 | Volume | 42,594 |
| Day high | $4.08 | Avg. volume | 158,618 |
| 50-day MA | $4.87 | Dividend yield | N/A |
| 200-day MA | $4.97 | Market Cap | 103.75M |
DarioHealth Corp. (DRIO) Company Bio
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device. It offers DarioEngage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy, hospitals, and distributors; and through online. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.
Latest DRIO News From Around the Web
Below are the latest news stories about DARIOHEALTH CORP that investors may wish to consider to help them evaluate DRIO as an investment opportunity.
Dario Selected as Digital Therapeutics Partner by a Top-Ten Digitally Enabled Pharmacy Benefits ManagerDarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced a new contract with a leading nationwide Pharmacy Benefits Manager (the "PBM") operating in 50 states to provide Dario's digital therapeutics, starting with the diabetes solution, to employer clients beginning in the second quarter of 2023. |
Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic SolutionDarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today a strategic partnership with Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, to deliver its cardiometabolic solution to Amwell customers. Dario's solution will be available through Amwell beginning in the second half of 2023. |
Dario Publishes New Research Demonstrating Digital Personalization of Pain Management with Adapted Machine LearningDarioHealth Corp. (Nasdaq: DRIO)(the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today new research published in Pain Reports investigating personalized efficacy of digital therapeutics for pain management, linking the reduction of back pain for users in a digital posture training program with the personalization of user journeys adapting machine learning models. |
The DarioHealth Corp. (NASDAQ:DRIO) Annual Results Are Out And Analysts Have Published New ForecastsThere's been a notable change in appetite for DarioHealth Corp. ( NASDAQ:DRIO ) shares in the week since its yearly... |
DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating ResultsDarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today reported financial results for the fourth quarter and full year 2022 and provided a corporate and commercial update. |
DRIO Price Returns
| 1-mo | -12.83% |
| 3-mo | -6.31% |
| 6-mo | -13.39% |
| 1-year | -32.49% |
| 3-year | -38.78% |
| 5-year | -86.98% |
| YTD | -6.31% |
| 2022 | -67.00% |
| 2021 | -9.24% |
| 2020 | 117.84% |
| 2019 | -57.95% |
| 2018 | -51.25% |
Continue Researching DRIO
Want to see what other sources are saying about DarioHealth Corp's financials and stock price? Try the links below:DarioHealth Corp (DRIO) Stock Price | Nasdaq
DarioHealth Corp (DRIO) Stock Quote, History and News - Yahoo Finance
DarioHealth Corp (DRIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...